# ![@NattaCop Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1487028804971155457.png) @NattaCop TheUrbanFarmer

TheUrbanFarmer posts on X about $ocgn, japan, company, money the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1487028804971155457/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1487028804971155457/c:line/m:interactions.svg)

- [--] Week [------] +25%
- [--] Month [------] +312%
- [--] Months [-------] +33%
- [--] Year [-------] -7.10%

### Mentions: [--] [#](/creator/twitter::1487028804971155457/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1487028804971155457/c:line/m:posts_active.svg)

- [--] Week [--] +100%
- [--] Month [--] +113%
- [--] Months [--] +53%
- [--] Year [---] +73%

### Followers: [-----] [#](/creator/twitter::1487028804971155457/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1487028804971155457/c:line/m:followers.svg)

- [--] Week [-----] +0.81%
- [--] Month [-----] +0.65%
- [--] Months [-----] +8%
- [--] Year [-----] +27%

### CreatorRank: [---------] [#](/creator/twitter::1487028804971155457/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1487028804971155457/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  19% [countries](/list/countries)  10% [stocks](/list/stocks)  2% [technology brands](/list/technology-brands)  1% [cryptocurrencies](/list/cryptocurrencies)  1% [celebrities](/list/celebrities)  1% [financial services](/list/financial-services)  1%

**Social topic influence**
[$ocgn](/topic/$ocgn) #7, [japan](/topic/japan) 7%, [company](/topic/company) 4%, [money](/topic/money) 4%, [pharma](/topic/pharma) 3%, [stocks](/topic/stocks) 3%, [$4503t](/topic/$4503t) 3%, [if you](/topic/if-you) 3%, [ceo](/topic/ceo) 2%, [flow](/topic/flow) 2%

**Top accounts mentioned or mentioned by**
[@ocugen](/creator/undefined) [@drsmusunuri](/creator/undefined) [@moreflax](/creator/undefined) [@cgtlive](/creator/undefined) [@rickabright](/creator/undefined) [@m3alaam](/creator/undefined) [@eduardo21881249](/creator/undefined) [@ivandeagreat](/creator/undefined) [@mahaaction](/creator/undefined) [@usfda](/creator/undefined) [@ocgn](/creator/undefined) [@antoniomi23137](/creator/undefined)

**Top assets mentioned**
[10s (10S)](/topic/$10s)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$ocgn Hey fam. 👨🌾 Unsure confused curious If so listen to what Im about to say closely because Im about to disclose something that only someone whos followed this company for years would catch. Ocugens OCU400 Phase [--] for RP started dosing in June [----]. The narrative youll hear from practically everyone is that the trial is still not fully enrolled. And sure thats half true. But people are so hung up on active enrollment that they completely miss how the trial is built. Phase [--] is two arms. One arm is [--] patients with RP caused by the RHO gene. The other arm is [--] patients with broad RP."  
[X Link](https://x.com/NattaCop/status/2021040473591492826)  2026-02-10T01:56Z [----] followers, [----] engagements


"$ocgn If Luxturnas global market was about [----] patients and still had Roche paying $4.3B for the company behind it makes you wonder what OCU400 for RHO will be worth when RHO RP alone sits around [------] patients worldwide roughly 33x bigger 🤔 😏 🍻"  
[X Link](https://x.com/NattaCop/status/2021944518246117631)  2026-02-12T13:48Z [----] followers, [----] engagements


"RT @Ocugen: This week is #PatientRecognitionWeek. Hear from Aiden an #OCU410ST Phase [--] participant diagnosed with #Stargardtdisease in hig"  
[X Link](https://x.com/NattaCop/status/2019914317089624122)  2026-02-06T23:21Z [----] followers, [--] engagements


"RT @Ocugen: Today we welcome Rita Johnson-Greene as our new CFO. With over [--] years of healthcare experience her deep expertise in cell a"  
[X Link](https://x.com/NattaCop/status/2020951281989452183)  2026-02-09T20:01Z [----] followers, [--] engagements


"RT @Ocugen: What an eventful week Ocugen participated in #JPM26 where CEO @drsmusunuri shared progress in advancing our novel modifier ge"  
[X Link](https://x.com/NattaCop/status/2012310361936924697)  2026-01-16T23:45Z [----] followers, [--] engagements


"$ocgn tick tock mfs. Next two months should be quite the show. 🚀😉🍻 $ocgn Last buying opportunity is from now to January. After that the rocket ignites with a consistent flow of partnership PR's as they gear up for BLA and commercialization. Capitalize or dont more for me 🤑 🍻 https://t.co/mIzSSM4h08 $ocgn Last buying opportunity is from now to January. After that the rocket ignites with a consistent flow of partnership PR's as they gear up for BLA and commercialization. Capitalize or dont more for me 🤑 🍻 https://t.co/mIzSSM4h08"  
[X Link](https://x.com/NattaCop/status/2017295415587312081)  2026-01-30T17:54Z [----] followers, [----] engagements


"RT @Ocugen: @CGT_Live highlights published Phase [--] results for #OCU410ST. Data shows meaningful visual & structural benefits in #Stargardtd"  
[X Link](https://x.com/NattaCop/status/2018467199569322316)  2026-02-02T23:30Z [----] followers, [--] engagements


"$ocgn great job fighting for the reauthorization. Congrats to you and the [----] to [--] million kids in the USA living with a rare disease. 👏 Wonderful news to see Congress pass legislation that reauthorizes the Rare Pediatric Disease Priority Review Voucher (PRV) program included in the Give Kids a Chance Act #BIOTechCaucus #GiveKidsaChance https://t.co/gwnO3Roj6b Wonderful news to see Congress pass legislation that reauthorizes the Rare Pediatric Disease Priority Review Voucher (PRV) program included in the Give Kids a Chance Act #BIOTechCaucus #GiveKidsaChance https://t.co/gwnO3Roj6b"  
[X Link](https://x.com/NattaCop/status/2019171824614224361)  2026-02-04T22:10Z [----] followers, [----] engagements


"Voyagers https://on.soundcloud.com/xzARNUSlkun0cmukyW https://on.soundcloud.com/xzARNUSlkun0cmukyW"  
[X Link](https://x.com/anyuser/status/2020322984544878928)  2026-02-08T02:25Z [----] followers, [---] engagements


"RT @Ocugen: CSO Arun Upadhyay shares how gene-agnostic modifier therapies could become a leading paradigm for treating major blindness dise"  
[X Link](https://x.com/NattaCop/status/2021349362581090369)  2026-02-10T22:23Z [----] followers, [--] engagements


"RT @drsmusunuri: Great to have Rita join us at a critical time for growth"  
[X Link](https://x.com/NattaCop/status/2021349406029775059)  2026-02-10T22:23Z [----] followers, [--] engagements


"This Fire https://on.soundcloud.com/4WD8jF0Au6uXNf12S2 https://on.soundcloud.com/4WD8jF0Au6uXNf12S2"  
[X Link](https://x.com/NattaCop/status/2022478997809221669)  2026-02-14T01:12Z [----] followers, [---] engagements


"$ocgn Luxturna treated 0.5% of the RP market thats a global population of under 10K patients. They still did $120M in year one got acquired for $1.4B then later bought by Roche for $4.8B for a one mutation product Now compare that to Ocu400/410/410ST which are gene agnostic and target broad IRD populations in RP GA and Stargardt. Just Ocu410ST alone is going after a market 30x50x the size Luxturna targeted Factor in FDA reforms cutting BLA reviews to [--] months orphan pricing now securing prices at $1.25M+ no matter how many diseases a drug treats and rewards like priority review vouchers that"  
[X Link](https://x.com/NattaCop/status/1947390858262942006)  2025-07-21T20:18Z [----] followers, [----] engagements


"$ocgn Most people have never heard of Ocugen. Thats exactly why its a goldmine. This isnt some hyped up penny stock. Its a pre commercial biotech entering the revenue phase backed by real science and billion dollar catalysts the market hasnt priced in yet. They recently landed a global licensing deal for only 1% of their products target market that proved they can generate massive upfronts milestone payments royalties in perpetuity and manufacturing revenue without dilution. This deal gave Ocugen the cash runway to file BLA next year. One more deal like that and suddenly their cash runway"  
[X Link](https://x.com/NattaCop/status/1949646735539921340)  2025-07-28T01:42Z [----] followers, [----] engagements


"$ocgn ahh the classic traders spamming outrage over ER lol. this pre revenue stock gets attacked every earnings ya its wild I know 🤪 anyways for any real investor 🙋♂ this is exactly what we wanted to see. all systems are go to bring blockbuster products to market back to back to back over the next [--] years. well soon learn who our well-established leader in pharmaceuticals in Korea partner is. look at that premium licensing deal 🤤 Stocks gonna make a lot of retail with foresight rich along with this all star management team whose incentives directly align with us. Ownership is tied to"  
[X Link](https://x.com/NattaCop/status/1951422913921605712)  2025-08-01T23:20Z [----] followers, [----] engagements


"mRNA is the sole reason Americans are waiting for a pandemic vax at all. [--] years of blocking every traditional platform egg cell vector just to force mRNA to the front. Billions in taxpayer funds funneled into synthetic tech while proven paths were sidelined. NIAID and select insiders got kickbacks. Now they pretend theres no plan B out there. There was Until they buried it"  
[X Link](https://x.com/NattaCop/status/1952877695819518150)  2025-08-05T23:41Z [----] followers, [----] engagements


"@RickABright Youve been involved with CEPI heres some data you helped surface that shows there are cheaper safer and still fast alternatives to mRNA. Platforms like viral vector tech are proven scalable and next Gen ready. Curious where you stand on these options now"  
[X Link](https://x.com/NattaCop/status/1952879456428974223)  2025-08-05T23:48Z [----] followers, [----] engagements


"Lmao Im sure taxpayers love knowing they were guinea pigs so Big Pharma could test run their next cash cow all funded by public dollars sold back at a premium all while safer options were buried. NIH insiders got royalties Fauci cashed checks and now sleep soundly convincing themselves itll save lives in the long run. Reality is it cost countless ones"  
[X Link](https://x.com/NattaCop/status/1952891885565165948)  2025-08-06T00:38Z [----] followers, [---] engagements


"No one denies mRNAs potential for gene therapy or future treatments. Thats not the conversation. Were talking about vaccines where Americans were forced into one rushed platform that failed to stop COVID cost more to produce store and deliver and left better options blocked. Taxpayers got scammed insiders got rich and pharma funneled billions while Americans died waiting for alternatives that were never given a chance. If youre saying all thats justifiable because mRNA might someday treat cancer cool. Lets talk. Odd they didnt fund it for that purpose from the start imo"  
[X Link](https://x.com/NattaCop/status/1952895083449335834)  2025-08-06T00:50Z [----] followers, [---] engagements


"mRNA isnt proven safe it failed to stop transmission required endless boosters and had higher adverse events like myocarditis. Viral vector clotting issues were tied to specific formulations and injection routes not the platform. Next-gen mucosal viral vector vaccines avoid that entirely its not even injected. CEPIs own data proves theyre fast scalable and effective"  
[X Link](https://x.com/NattaCop/status/1952897291435819030)  2025-08-06T00:59Z [----] followers, [--] engagements


"Call me fucking stupid Youve been pushing pharma dogma for years claiming mRNA has zero safety concerns. Pfizer doesnt even back you their own trial data showed tens of thousands of serious adverse reactions and over a thousand deaths. Thats why they fought to hide it for [--] years. You didnt see a loved one drop dead after the shot. That doesnt make you informed doesnt make you right just lucky and dangerously fucking stupid. https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf"  
[X Link](https://x.com/NattaCop/status/1952906718436085881)  2025-08-06T01:36Z [----] followers, [---] engagements


"Novavax was sidelined for years just like other traditional options like Covaxin while the gov funneled billions into mRNA and forced it down Americans throats until 80%+ had already taken it. Only after that did Novavax get approved but dont leave out a key fact. Its only approved for people who hadnt already taken mRNA. Thats less than 20% of the country. You think dropping an alternative years late restricted to a sliver of the population shows a fair market"  
[X Link](https://x.com/NattaCop/status/1952909658626376185)  2025-08-06T01:48Z [----] followers, [---] engagements


"CEPIs own data shows other platforms like viral vector and protein subunit could reach human trials within roughly the same [--] week window after mRNA candidates were designed. Yet only mRNA got billions in funding and priority approval despite being FAR more expensive to manufacture requiring new ultra cold storage infrastructure nationwide expiring multitudes faster and offering short lived non sterilizing immunity. Meanwhile the cheaper proven platforms with room temp stability and proven long term durability were sidelined. All this for a few weeks of speed That not science bud. Thats"  
[X Link](https://x.com/NattaCop/status/1952917048646091243)  2025-08-06T02:18Z [----] followers, [---] engagements


"Market hasnt priced in any of these catalysts yet. Right now were a pre rev bio with the cash to get us to BLA next year but not all the way to commercialization/revenue. The market reads that as dilution ahead and values us like it. Theyre looking at it broadly they dont know managements incentives are tied to fixed rate warrants meaning their upside only comes if the stock goes up. Reality is if youve done the research management will avoid major dilution because it directly benefits them. The company has already shown they can bring in cash by other means partnerships with big upfronts non"  
[X Link](https://x.com/NattaCop/status/1953605705640161798)  2025-08-07T23:54Z [----] followers, [---] engagements


"No Return Ticket https://on.soundcloud.com/HrQV6kbdE0WfBieWU3 https://on.soundcloud.com/HrQV6kbdE0WfBieWU3"  
[X Link](https://x.com/NattaCop/status/1953635751889186988)  2025-08-08T01:53Z [----] followers, [---] engagements


"$ocgn I hear about products all the time and often theyre brought up because people view them as a threat to this companies pipeline. Sanofi's early stage Gene Therapy for Wet AMD being the latest. I like explaining why they are not because it shows exactly why what we own is special. So heres why it is silly to see Sanofis as a threat when it is actually the opposite. This is just one story but the ending mirrors all the others. Sanofis drug is just another anti VEGF product for wet AMD only trying to cut the amount of shot visits patients need. Its basically J&Js Covid vaccine DNA delivered"  
[X Link](https://x.com/NattaCop/status/1968492365255205366)  2025-09-18T01:48Z [----] followers, [----] engagements


"@m3alaam The cure to blindness first of many partnerships announced Ocu400 will be in Korea. Deal has extremely bullish terms for us with a top [--] Korean pharma. My page is full of details about this stock. 🍻"  
[X Link](https://x.com/NattaCop/status/1968754746128302135)  2025-09-18T19:11Z [----] followers, [---] engagements


"$ocgn 1st off fam winning feels good. Bears your Ls are stacking nice. Hows that subscription 😜 2nd see how non of these analysts know the damn price of our drug tossing numbers like $200K lol. The price is on Ocugen's slide these peeps are lazy and overworked. Writing analyst articles about a stocks product giving PTs and everything and they dont even know the price. 🤯🤦♂ And no he's not being conservative. $750K in EU and $850K US is the absolute floor $1.5m the ceiling. No pharma is spending tens of millions on R&D for a drug not knowing what insurers are willing to pay for it. This is"  
[X Link](https://x.com/NattaCop/status/1970663439153725592)  2025-09-24T01:35Z [----] followers, [----] engagements


"$ocgn a stock question answer that shows why the fundamentals here = growth. 💸 🏦 Management owns a total of 4.51m right to buy fixed rate options that are mostly vested (around 500k fully vest in 2026). Shankar for example owns 1.475m fixed at $1.25 and he doesn't need to exercise them for another [--] years and [--] months. You'd want to wait as long as you possibly can for the highest SP to exercise them because that = more ownership for free. A stock at $100 means that every share bought at $1.25 gets you [--] shares for free that's 1.18m shares that are worth $118M for free. This fundamental"  
[X Link](https://x.com/NattaCop/status/1971101744869605837)  2025-09-25T06:37Z [----] followers, [----] engagements


"$ocgn company has nothing but big news to announce for months and years to come. Easiest buy there ever was. 💸 🏦 🚀 🌙"  
[X Link](https://x.com/NattaCop/status/1973779213196083662)  2025-10-02T15:56Z [----] followers, [----] engagements


"$ocgn Bullish trends meet news packed conferences and business updates. Got to love where this is heading 🤑 EZ 💸 🏦 🍻 Nothing like hanging out and talking about stocks. What nobody is talking about is the weekly 200MA. Thanks for pointing it out @Eduardo21881249 . https://t.co/OGtcem6Kll Nothing like hanging out and talking about stocks. What nobody is talking about is the weekly 200MA. Thanks for pointing it out @Eduardo21881249 . https://t.co/OGtcem6Kll"  
[X Link](https://x.com/NattaCop/status/1973997836946874746)  2025-10-03T06:25Z [----] followers, [----] engagements


"$Ocgn This👇is what BARDA is looking for. Sound familiar"  
[X Link](https://x.com/NattaCop/status/1592118702409146370)  2022-11-14T11:34Z [----] followers, [--] engagements


"$ocgn A revolutionary breakthrough in gene therapy. 👏"  
[X Link](https://x.com/NattaCop/status/1885044604837519402)  2025-01-30T19:17Z [---] followers, [----] engagements


"$ocgn This is a critical part imo. The lenders hold a senior security interest in Ocugens assets including its intellectual property as collateral. This means that if Ocugen wants to license or transfer its IP it would need lender approval since the lenders have a lien on it. If a big pharma deal were negotiated and Ocugen sought lender approval it would make perfect sense for the lender to respond Well release the IP for licensing once you pay off the secured portion of the loan and wed gladly accept shares. This is what we witnessed imo"  
[X Link](https://x.com/NattaCop/status/1885752554765930901)  2025-02-01T18:10Z [---] followers, [----] engagements


"$ocgn Oh is it nice to see validation catch up to very bullish speculation. Soon the biggest news in companys history drops. 🍻🚀🌙👽 $ocgn This is a critical part imo. The lenders hold a senior security interest in Ocugens assets including its intellectual property as collateral. This means that if Ocugen wants to license or transfer its IP it would need lender approval since the lenders have a lien on it. https://t.co/sMmeqTBXtH $ocgn This is a critical part imo. The lenders hold a senior security interest in Ocugens assets including its intellectual property as collateral. This means that"  
[X Link](https://x.com/NattaCop/status/1888026563670954366)  2025-02-08T00:46Z [---] followers, [----] engagements


"$ocgn 🐂 https://www.investing.com/news/analyst-ratings/ocugen-shares-rise-as-hc-wainwright-lifts-price-target-to-8-93CH-3867565 https://www.investing.com/news/analyst-ratings/ocugen-shares-rise-as-hc-wainwright-lifts-price-target-to-8-93CH-3867565"  
[X Link](https://x.com/NattaCop/status/1890075979592397082)  2025-02-13T16:30Z [---] followers, [----] engagements


"$ocgn Next Big Pharma 💯 🚀"  
[X Link](https://x.com/NattaCop/status/1891859408524615759)  2025-02-18T14:36Z [---] followers, [----] engagements


"$ocgn soon well learn who our partners are in Korea. The Korean deal conservatively projects $2.19b in total manufacturing revenue with $506m in profit after treating half of Koreas RP market (7500 patients). Even at just 3% yearly market capture (of [----] patients) Ocugen would still generate $65.8m/year in manufacturing revenue for Korea alone. Now add $2b+ in royalties (of [----] patients treated) plus millions in milestone payments. Whats the value of a deal like this with a company that will have no problem executing it Imo Id value it with more confidence. 🍻"  
[X Link](https://x.com/NattaCop/status/1950729660528197799)  2025-07-31T01:26Z [----] followers, [----] engagements


"$ocgn FDA is opening the door for rare disease CGT (Cell and Gene Therapies) with self controlled trials external controls and registry follow up saving years and millions in development. This directly accelerates OCU400 and OCU410ST bringing them to market at record speed 🍻 #OCUGEN $OCGN.rare disease designation 👇👇👇👇 https://t.co/VggIqSNwpu #OCUGEN $OCGN.rare disease designation 👇👇👇👇 https://t.co/VggIqSNwpu"  
[X Link](https://x.com/NattaCop/status/1974228605401203096)  2025-10-03T21:42Z [----] followers, [----] engagements


"$ocgn Very interesting Job description specifically: in-plant leadership for manufacturing at Ocugen technical expertise and leadership to Ocugens external manufacturing partners lead technology transfers collaborate across the network This screams a hub and spoke model. Ocugens Malvern facility being the hub that runs the playbook and launch supply. Future partners are the spokes via tech transfer. Yet the only public partner so far is Korea where Ocugen keeps manufacturing control. For India my pick is Bharat Biotech. They have growing CGT capacity so that deal likely trades local"  
[X Link](https://x.com/NattaCop/status/1974469306542072308)  2025-10-04T13:39Z [----] followers, [----] engagements


"$ocgn Company has the drugs the expertise and a way to cross the blood brain barrier. As an early backer betting on a revolutionary concept Ive watched this modifier gene approach reshape the gene therapy landscape and how we tackle rare diseases. With concept now a reality does the future stop at rare diseases Not even remotely close. This is the start of a paradigm shift in healthcare. The days of bandaid subscriptions are ending and the age of real cures is coming. Practically everyone has been or will be affected by diseases like Alzheimers Parkinsons autism etc. The question isnt if this"  
[X Link](https://x.com/NattaCop/status/1975725813153866053)  2025-10-08T00:51Z [----] followers, [----] engagements


"$ocgn Most will see Phase [--] for GA in [----] and shrug. The ones who know GA the therapy and this market understand the gravity of what was just announced. Dr. Jay Chhablan the Vice Chair of Clinical Trials at the University of Pittsburgh Medical Center Vision Institute just said the [--] month OCU410 data already looks superior to the FDA approved drugs when he compared them side by side. Retail needs to understand why this sets OCU410 up as one of the most valuable medicines ever lined up to hit the market. Why Im saying that OCU400 family keeps winning. OCU400 for IRDs OCU410ST for Stargardt"  
[X Link](https://x.com/NattaCop/status/1977731277647384699)  2025-10-13T13:40Z [----] followers, [----] engagements


"$ocgn breakthrough therapy after therapy continues to get nothing but stellar trial results. This will be the biggest pharma in the world. 💯 📠"  
[X Link](https://x.com/NattaCop/status/1978576745339961583)  2025-10-15T21:40Z [----] followers, [----] engagements


"$ocgn like a glove 🍻 FDA will be proactive in advancing decisions on medicines serving a key national priority: affordability domestic production or meeting an unmet public health need. https://t.co/oUuEsAnBQ2 FDA will be proactive in advancing decisions on medicines serving a key national priority: affordability domestic production or meeting an unmet public health need. https://t.co/oUuEsAnBQ2"  
[X Link](https://x.com/NattaCop/status/1978937545011388622)  2025-10-16T21:34Z [----] followers, [----] engagements


"$ocgn welcome @drsmusunuri biotech GOAT. May more see just how much brighter youre making the world. 🍻"  
[X Link](https://x.com/NattaCop/status/1979231819305451544)  2025-10-17T17:03Z [----] followers, [----] engagements


"$ocgn Company Galactic 🤣 ☠"  
[X Link](https://x.com/NattaCop/status/1979244894087782577)  2025-10-17T17:55Z [----] followers, [----] engagements


"$ocgn couldnt ask for better results. 🍻🔥"  
[X Link](https://x.com/NattaCop/status/1979444405691126129)  2025-10-18T07:08Z [----] followers, [----] engagements


"🧵 $ocgn Hot take: stocks push to $2.5 will be followed by a Japan partnership announcement and Astellas clearly looks like the partner. Why Astellas"  
[X Link](https://x.com/NattaCop/status/1979695816655937621)  2025-10-18T23:47Z [----] followers, [----] engagements


"Astellas is built for retina after the Iveric deal. Huge Japan field force. Real PMDA muscle. No RP conflict of interest. They know pricing and access and they move paperwork fast. How does Japans market look"  
[X Link](https://x.com/NattaCop/status/1979695818518196503)  2025-10-18T23:47Z [----] followers, [---] engagements


"Use Korea as the benchmark. Korea deal was about 7.5M upfront with [--] percent royalties and Ocugen supplying drug. Scale by market size plus Japan pricing power and the math gets spicy. Spicy"  
[X Link](https://x.com/NattaCop/status/1979695823043887396)  2025-10-18T23:47Z [----] followers, [---] engagements


"My range for a Japan only license Worst case 25M to 45M upfront Base 50M to 80M upfront Stretch 90M to 120M upfront Royalties [--] to [--] percent Ocugen likely keeps manufacturing on a cost plus margin. Math check"  
[X Link](https://x.com/NattaCop/status/1979695827099766893)  2025-10-18T23:47Z [----] followers, [---] engagements


"Quick math check Assume bilateral price in Luxturna class. Treat [---] to [---] patients per year as capacity ramps. That is roughly 15B to 70B in yearly net sales. About 100M to 470M dollars at simple FX. At [--] percent royalty that is 20M to 100M a year to Ocugen before any supply margin. Speed"  
[X Link](https://x.com/NattaCop/status/1979695829998039383)  2025-10-18T23:47Z [----] followers, [---] engagements


"Why Japan can move fast PMDA can accept foreign clinical data under ICH E5. Examples: Luxturna and Zolgensma. No need to redo the world. Our package fits that playbook"  
[X Link](https://x.com/NattaCop/status/1979695831684112697)  2025-10-18T23:47Z [----] followers, [---] engagements


"Bottom line If Astellas takes Japan the package lands at a 3x to 6x multiple of Korea with double digit royalties and Ocugen keeping the manufacturing lever. This deal is going to be so f**king 🔥😉🤑 Do you Im am long. 🍻"  
[X Link](https://x.com/NattaCop/status/1979695833311514860)  2025-10-18T23:47Z [----] followers, [---] engagements


"$ocgn Why build an AI team in India Because Ocugens gene agnostic platform has shown it can correct over [---] mutations. Recent FDA and global moves let platform therapies expand into related mutations or indications without a brand new BLA or new pricing negotiation. Many drugs could treat more but the risk stopped companies from trying. That barrier is gone now. For a platform that addresses over [---] mutations across multiple diseases this opens a path to reach millions who have nothing today. AI will help companies map the addressable markets design smarter trials and process the data at"  
[X Link](https://x.com/NattaCop/status/1980489896709247276)  2025-10-21T04:22Z [----] followers, [----] engagements


"$ocgn very few understand yet but it will be very apparent to everyone soon. 🍻"  
[X Link](https://x.com/NattaCop/status/1981550953267679502)  2025-10-24T02:38Z [----] followers, [----] engagements


"$ocgn If you are invested or thinking about it watch the latest panel discussion with the CEO Shankar. You have to fill your name and email and then the video will pop up. Its 40mins+ long but very worth the watch. Any investor or potential investor who watched this would put their money on Ocugen. While everyone else is focused on small progress Ocugen is focused on a paradigm shift and their drugs have proved that theyre just that. Basic summary: Others talked about how there's plenty of room currently in the market for other treatment options that they see commercial success for drugs that"  
[X Link](https://x.com/NattaCop/status/1982244501784768954)  2025-10-26T00:34Z [----] followers, [----] engagements


"$ocgn New peer reviewed paper on OCU400: Perfect safety Vector stays in the eye no anti NR2E3 issues NR2E3 expression holds This paper de risks our BLA and sweetens the math for partnership. Bullish sentiment tailwind inbound I think so. 🍻"  
[X Link](https://x.com/NattaCop/status/1983651447746285917)  2025-10-29T21:45Z [----] followers, [----] engagements


"$ocgn this stock is considered too risky in the eyes of big money and institutions. With phase [--] trials ongoing these major funds will wait until more data/BLA before investing. For retail who actually follow the pipeline have watched trial after trial get stellar results of 100% safety and 100% efficacy. When data rolls in analysts have to do real math. Weve already seen $8+ SP targets with most modeling 100k pricing. Our product and Gene therapy comps in general will live around $850k to $1.25m. First drug to market is for Retinitis Pigmentosa. Hundreds of thousands of patients worldwide"  
[X Link](https://x.com/NattaCop/status/1985431549635150027)  2025-11-03T19:39Z [----] followers, [----] engagements


"$ocgn Exactly the update I wanted to see. OCU400 set to start a rolling BLA in 1H [----]. OCU410ST 50% enrolled and on track for a 1H [----] BLA filing. Cash on hand extends into [----] if Aug warrants are fully executed. EMA/CHMP accepted a single U.S. trial for the Stargardt MAA. Korea license for OCU400 reiterated $7.5m upfront milestones structured as $1.5M per $15M of sales(projecting $180M+ in first [--] years off milestone payments) 25% royalties and Ocugen supplies drug (keeping manufacturing control). OCU200 enrollment targeted to complete 4Q [----]. OCU410(GA) full phase [--] data in 1Q 2026."  
[X Link](https://x.com/NattaCop/status/1986081806177952037)  2025-11-05T14:42Z [----] followers, [----] engagements


"$ocgn We saw patient going blind after patient go in and get treated. Then we saw tearful and joyous testimonials every year since. 100% efficacy. 100% safety. And thats not just one product. Were seeing it platform wide RP Stargardt GA and now autism looks to be next. Got our eyes on Alzheimers Parkinsons and more too. You can see a pre Rev bio just another speculative play or try to gamble on the SP as it fluctuates cents daily. Im seeing reality and science tell a once in a lifetime story and cant help but capitalize on the most discounted bio on the market.🍻"  
[X Link](https://x.com/NattaCop/status/1986434836714922324)  2025-11-06T14:05Z [----] followers, [----] engagements


"No bp buyout theyll continue to announce regional partnerships like the Korean partnership until the rest of world(outside of US/EU) is covered leading up to commercialization. Best case is FDA head Marty gives OCU400/OCU410 a congressional PRV. Company has [--] BLAs lined up for [--] products 2026(OCU400)/2027(OCU410ST)/2028(OCU410). 🍻"  
[X Link](https://x.com/NattaCop/status/1986644001009901583)  2025-11-07T03:56Z [----] followers, [---] engagements


"$ocgn load up for the many partnership PRs to come. Then hold for the [--] BLAs and billions in revenue. A bio with a $400M market cap with [--] mega blockbuster drugs lined up for BLA year after year after year. Trial data shows 100% efficacy 100% safety. Where this investment is going is beyond obvious own your piece while its quiet then enjoy when its loud. 🍻"  
[X Link](https://x.com/NattaCop/status/1987943273386987653)  2025-11-10T17:59Z [----] followers, [----] engagements


"$ocgn this revolutionary approach is about to change the world for the better. So exciting. #OCUGEN $OCGN 👇👇👇 https://t.co/kqRHW75Fvh https://t.co/9djJwDPiHb #OCUGEN $OCGN 👇👇👇 https://t.co/kqRHW75Fvh https://t.co/9djJwDPiHb"  
[X Link](https://x.com/NattaCop/status/1987980680140411307)  2025-11-10T20:28Z [----] followers, [----] engagements


"Left Alone https://on.soundcloud.com/qfR1x4hbLpPPRf0HAS https://on.soundcloud.com/qfR1x4hbLpPPRf0HAS"  
[X Link](https://x.com/NattaCop/status/1989888850781778177)  2025-11-16T02:50Z [----] followers, [---] engagements


"$ocgn This is what everything points to. The playbook at hand. What needs to happen to make this start up story one of the most successful in Pharma. And it all comes down to [----]. From managements incentives to the companys needs everything points to growing the company as much as they possibly can in [----] leading up to their global commercial launch. Not only does management need to increase the SP by multitudes to max out their PSUs which would account for a big chunk of their ownership before the lockout window closes later [----] but the company also needs to gear up for the global launch"  
[X Link](https://x.com/NattaCop/status/1990228737200468246)  2025-11-17T01:21Z [----] followers, [----] engagements


"Lilly In The Crawlspace https://on.soundcloud.com/qVGJRScHAdqyAjdLta https://on.soundcloud.com/qVGJRScHAdqyAjdLta"  
[X Link](https://x.com/NattaCop/status/1990881524301115875)  2025-11-18T20:35Z [----] followers, [---] engagements


"$Ocgn for anyone confused about Ocu410 phase [--] six month data. Think of GA as a dead patch on the eye that keeps spreading. Current drugs like Syfovre and Izervay only slow how fast that patch grows. They do not actually bring vision back and they need injections every single month just to keep losing vision a little slower. A single shot of OCU410 is showing a 27% reduction at [--] months. Those results alone would position Ocu410 to take over the entire market. It does not take a rocket scientist to see that most people would rather get one shot with better results than live on [--] shots yearly"  
[X Link](https://x.com/NattaCop/status/1993132366307766376)  2025-11-25T01:39Z [----] followers, [----] engagements


"$ocgn This framework is quietly screaming modifier gene platform. Ocugens platform hits every box. Box one mechanism based not diagnosis based. One modifier program you can apply across a huge range of retinal diseases and more. Box two Human results showing vision improvement or stabilization across [---] plus different mutations tied to countless retinal diseases and more. Box three US manufacturing and long term safety. Ocugen has domestic GMP capacity and years of follow up with no safety concerns. For a pathway that leans on ongoing real world evidence and long term safety this modifier"  
[X Link](https://x.com/NattaCop/status/1993741850201772197)  2025-11-26T18:01Z [----] followers, [----] engagements


"@MAHA_Action With a financial interest too. So is he an opportunistic monster or just pure evil Bet the full story gets told only after hes gone. Guy deserves to be in a cell and thats just me phrasing it nicely. @US_FDA The American people deserve the truth. FDA do you remember Covaxin The traditional whole-virion vaccine that you forced to jump through every bureaucratic hoop while you were fast-tracking mRNA boosters based on trials conducted on just [--] mice You urged the company to seek https://t.co/FqC9TtQvZP @US_FDA The American people deserve the truth. FDA do you remember Covaxin The"  
[X Link](https://x.com/NattaCop/status/1993890959793508367)  2025-11-27T03:53Z [----] followers, [---] engagements


"$ocgn this is the only report Ive read yet that actually gets our price tag right. Its extremely modest modeling a 80k US market(most estimates are just north of 100k) and has OCU400 TAM at just under 50%(Ocugen says 90%+). So 38k TAM and they have a super conservative ramp up of .5% year [--] then 1% 2% 3% and tops at 4% when Ocugen projections are double that. Their PT only models Ocu400 and lists everything else as upside. Their [--] month pt forecast is $15. Even tho theyre very conservative and only factor in OCU400 its by far the best analysis report Ive seen to date. 🔥 🍻"  
[X Link](https://x.com/NattaCop/status/1995860520390590607)  2025-12-02T14:20Z [----] followers, [----] engagements


"$ocgn imagine knowing all this info and not taking advantage. I couldnt fathom it. Once in a lifetime opportunity here and thats putting it lightly. 🍻 https://m.youtube.com/watchv=9quXTbPV5gA&t=49s&pp=2AExkAIB https://m.youtube.com/watchv=9quXTbPV5gA&t=49s&pp=2AExkAIB"  
[X Link](https://x.com/NattaCop/status/1996746680088383585)  2025-12-05T01:01Z [----] followers, [----] engagements


"Psh you talk nonsense. Any idea how much blindness diseases cost society The yearly economic burden of blindness is astronomical costs society and insurers. You think insurers cover products like Luxturna out of the goodness of their heart Lmao no they do it because they end up making money. You talk like a parent is going to get a $1M bill in the mail. Thats not how gene therapy works. Insurers and health systems pay because curing blindness is cheaper than funding a lifetime of disability. Yeah well just front the bill for 15-20 years waiting for a bio similar gene therapy 🤪 I also see"  
[X Link](https://x.com/NattaCop/status/1997040207871516679)  2025-12-05T20:27Z [----] followers, [---] engagements


"$ocgn fyi when a company spends time lobbying CMS(centers for Medicare and Medicaid services) they do so to get reimbursement squared away before product launch. Making all the moves I wanna see. 🍻 💸 🏦 🐂"  
[X Link](https://x.com/NattaCop/status/1998911444293923207)  2025-12-11T00:23Z [----] followers, [----] engagements


"$ocgn you all better be loading up [----] and everything weve been waiting for is just around the corner. 🍻 💸 🏦 🐂"  
[X Link](https://x.com/NattaCop/status/2000681939162878147)  2025-12-15T21:38Z [----] followers, [----] engagements


"$ocgn throwback to penny days. Nothing but growth since then. If you didnt listen back then then listen to me now. Buy yourself some shares of Ocugen before everyone else does and hold onto them. From $1 to $10s to $100s thisll go. 📠 💸 🏦 🐂"  
[X Link](https://x.com/NattaCop/status/2001656175704813931)  2025-12-18T14:09Z [----] followers, [----] engagements


"$ocgn got to love PSUs. 🚀 https://x.com/nattacop/status/1990228737200468246s=46&t=YJcqBPuRYY4dOYoVQP8SvQ $OCGN #OCUGEN 👇 👇 👇 👇 Great news imo https://t.co/69Q1w6wTjM https://x.com/nattacop/status/1990228737200468246s=46&t=YJcqBPuRYY4dOYoVQP8SvQ $OCGN #OCUGEN 👇 👇 👇 👇 Great news imo https://t.co/69Q1w6wTjM"  
[X Link](https://x.com/NattaCop/status/2001787185004191981)  2025-12-18T22:50Z [----] followers, [----] engagements


"$ocgn The question that I see constantly plaguing shareholders is how could Ocugen be valued so low while others like BLTE with far less promise are valued so much higher I went and deep dived BLTE hoping I could help people understand the difference and what I am about to share hopefully will open some eyes to how these pre revs get their value. If you look at BLTE it is simple. They have a drug with promising clinical data and a market to enter once approved. That is basically it. So why has the market held BLTE over $1B before approval and valued them around $5.8B today while Ocugen sits"  
[X Link](https://x.com/NattaCop/status/2002578102745284777)  2025-12-21T03:13Z [----] followers, [----] engagements


"$ocgn appreciate you brother 🔥 February/March is the time for those big partnership PRs. Imo well see Japan first and then maybe EU 😉🍻 $OCGN OCU400: world's first gene therapy to cure broad RP and LCA. Everyone's watching. BARDA funding for Project NexGen: paperwork's in waiting for the word. Russell 3000: review on June 28th. #GeneTherapy #OCU400 https://t.co/CUV9ND32Wn $OCGN OCU400: world's first gene therapy to cure broad RP and LCA. Everyone's watching. BARDA funding for Project NexGen: paperwork's in waiting for the word. Russell 3000: review on June 28th. #GeneTherapy #OCU400"  
[X Link](https://x.com/NattaCop/status/2003563609264390406)  2025-12-23T20:29Z [----] followers, [----] engagements


"$ocgn Imagine the first approved gene therapy ever. One that targeted an ultra rare mutation during a time when genetic screenings were barely happening. Luxturnas total market was 5k patients globally. It was also the most expensive drug ever made at the time. For a product these are some massive hurdles to overcome. Despite all of this they still had a respectable market penetration that generated over $250m over [--] years. To put this in perspective if Ocugen performed at the same level as Luxturna did theyd make $50b dollars in that same time frame Gene therapy is well known now screening"  
[X Link](https://x.com/NattaCop/status/2005115238774178196)  2025-12-28T03:15Z [----] followers, [----] engagements


"Think the most fair way is to base it on what the company projects. What they project is 3% - 15% and revenue projections implies low single digits year one and ramping up over time. 1.5-3% penetration yearly is very reasonable imo and equates to billions in yearly revenue from solely US/EU markets"  
[X Link](https://x.com/NattaCop/status/2005286664961413426)  2025-12-28T14:36Z [----] followers, [--] engagements


"Quiet Fever https://on.soundcloud.com/31Xo9zwOJ3ePjzSVaO https://on.soundcloud.com/31Xo9zwOJ3ePjzSVaO"  
[X Link](https://x.com/NattaCop/status/2006066470825107759)  2025-12-30T18:14Z [----] followers, [---] engagements


"$ocgn very conservative indeed 📠 🚀 🍻 @ocgn #Ocugen #ocufam Price target ranges from $7 to $15. Seems conservative to me but what do I know. Im just a dumb kid from Arkansas (said either Sam Walton or Bill Clintoncant remember. Doesnt matter) 👇 https://t.co/tuURc6sIhX @ocgn #Ocugen #ocufam Price target ranges from $7 to $15. Seems conservative to me but what do I know. Im just a dumb kid from Arkansas (said either Sam Walton or Bill Clintoncant remember. Doesnt matter) 👇 https://t.co/tuURc6sIhX"  
[X Link](https://x.com/NattaCop/status/2007219252315730149)  2026-01-02T22:35Z [----] followers, [----] engagements


"$ocgn If youre an investor and miss out on Ocugens massive run this year. Its time to re evaluate your whole life. https://www.ad-hoc-news.de/boerse/news/ueberblick/ocugen-s-pivotal-year-clinical-data-and-financial-runway-in-focus/68444233# https://www.ad-hoc-news.de/boerse/news/ueberblick/ocugen-s-pivotal-year-clinical-data-and-financial-runway-in-focus/68444233#"  
[X Link](https://x.com/NattaCop/status/2007221379998068821)  2026-01-02T22:44Z [----] followers, [----] engagements


"Reality fam. No blame no accusation. These awards were shareholder approved earned and granted on the timeline we all knew. Good data leads to rerates and partnerships. Companies pump fluff all the time but Ocugen has had zero need to and thats my point. They just need to execute and let the data and deals do the talking. Im just explaining the same incentive structure that made Elon the richest man in the world. And its going to make Shankar and shareholders a whole lot too. 🍻 https://twitter.com/i/web/status/2009171313332769225 https://twitter.com/i/web/status/2009171313332769225"  
[X Link](https://x.com/NattaCop/status/2009171313332769225)  2026-01-08T07:52Z [----] followers, [---] engagements


"$ocgn Almost like the FDA regulation changes were tailored for us lol. [--] BLAs a gene agnostic platform millions of patients tens of billion dollar markets are ours for the taking. You cant be more bullish about the future than an Ocugen investor is. 🍻"  
[X Link](https://x.com/NattaCop/status/2010531383635275930)  2026-01-12T01:56Z [----] followers, [----] engagements


"$ocgn so our gene agnostic platform tech is about to prove itself and get global recognition. tech that cures diseases affecting millions. data coming in that supports a BLA aiming at markets worth tens of billions. then [--] more BLAs shortly after and one of those products is worth insanely vastly more. Were talking projections for annual peak revenue hitting $40b across [--] products with more to come. and every big money concern thats kept this stock suppressed this long is about to disappear. Meanwhile BLTE is projecting $1b annual peak sales with a slow ramp up and the market values them"  
[X Link](https://x.com/NattaCop/status/2011278769932091553)  2026-01-14T03:26Z [----] followers, [----] engagements


"$ocgn isnt that the truth. And thats the whole reason why Im here. 😉 The stock price isnt reflecting the pipeline at all yet. Market still treats this like a maybe one day bio but that one day is getting real close. Re rates happen when two things become obvious: [--]. a product is coming to market [--]. the company has the cash runway to reach revenue Thats when the market starts pricing in everything people ignore right now platform tech follow on indications partnerships the whole compounding machine. And it always happens faster than the average retailer can react. Todays news is the perfect"  
[X Link](https://x.com/NattaCop/status/2011994026900365608)  2026-01-16T02:48Z [----] followers, [----] engagements


"@antonio_mi23137 Real pricing is $450k. 🍻"  
[X Link](https://x.com/NattaCop/status/2012607339241586749)  2026-01-17T19:25Z [----] followers, [--] engagements


"$ocgn Last buying opportunity is from now to January. After that the rocket ignites with a consistent flow of partnership PR's as they gear up for BLA and commercialization. Capitalize or dont more for me 🤑 🍻"  
[X Link](https://x.com/anyuser/status/1995588081806884878)  2025-12-01T20:17Z [----] followers, [----] engagements


"Say Less https://on.soundcloud.com/KXCkXn1Tv2r5X5CShE https://on.soundcloud.com/KXCkXn1Tv2r5X5CShE"  
[X Link](https://x.com/anyuser/status/2016671618869907678)  2026-01-29T00:35Z [----] followers, [---] engagements


"The American people deserve the truth. FDA do you remember Covaxin The traditional whole-virion vaccine that you forced to jump through every bureaucratic hoop while you were fast-tracking mRNA boosters based on trials conducted on just [--] mice You urged the company to seek approval through a U.S. BLA trial and they didspending over $100 million on a massive Phase [--] trial that yielded top-line data showing broad protection against all variants of concern. Yet despite this you never approved an alternative traditional vaccine option after they successfully navigated your obstacle course. Why"  
[X Link](https://x.com/anyuser/status/1826770960487514134)  2024-08-22T23:58Z [----] followers, 143.4K engagements


"RT @MoreFlax: $OCGN #OCUGEN 👇 👇 👇 It amazes me to see how many people are oblivious to Ocugen's pipelines. Why invest in a company without"  
[X Link](https://x.com/anyuser/status/2018383756634267722)  2026-02-02T17:59Z [----] followers, [--] engagements


"$ocgn Next week is gonna be crazy cant wait. 😜👽🚀"  
[X Link](https://x.com/NattaCop/status/1759001959233945740)  2024-02-17T23:48Z [----] followers, [----] engagements


"$ocgn the drug we own covers most retinal diseases a true master regulator. Winning 💰🏦"  
[X Link](https://x.com/anyuser/status/1808105348538290260)  2024-07-02T11:48Z [----] followers, [----] engagements


"$ocgn load the 🛥 💸 🏦 #OCUGEN. Vanguard has about 6% ownership.obviously it is intentionally with one thought in mind.to make more money 💰 🤑🤑🤑 👇👇👇 https://t.co/QyAw1cuxIu #OCUGEN. Vanguard has about 6% ownership.obviously it is intentionally with one thought in mind.to make more money 💰 🤑🤑🤑 👇👇👇 https://t.co/QyAw1cuxIu"  
[X Link](https://x.com/NattaCop/status/1854156220514607195)  2024-11-06T13:37Z [----] followers, [----] engagements


"$ocgn Did you know mice can model autism biology In those models you see the same direction as humans with RORA turned down in the brain. In a maternal diabetes model where pups reliably show autism like behaviors giving the pregnant dams a RORA agonist (SR1078) led to offspring with a substantial decrease in social and vocalization deficits. Turning up RORA after birth in standard adult models and symptoms like repetitive behaviors drop. In summary RORA shows prevention before birth and symptom control after birth in mice. Its no wonder why autism is on Ocugens radar. They possess a"  
[X Link](https://x.com/anyuser/status/1976331633042313318)  2025-10-09T16:59Z [----] followers, [----] engagements


"$ocgn You could of invested in [---] start up biotechs with gene agnostic drugs targeting our markets. The odds of your investment paying off was 0% up until now. Know what you own like really a once in a lifetime bet doesn't even do it justice. 🍻"  
[X Link](https://x.com/NattaCop/status/1859960199890788643)  2024-11-22T14:00Z [----] followers, [----] engagements


"$ocgn Flatline https://on.soundcloud.com/GvoqveOcD8GNcAdndS https://on.soundcloud.com/GvoqveOcD8GNcAdndS"  
[X Link](https://x.com/anyuser/status/2013288125926093156)  2026-01-19T16:31Z [----] followers, [----] engagements


"$ocgn opportunity of a lifetime. 🍻"  
[X Link](https://x.com/anyuser/status/2013621217819873517)  2026-01-20T14:34Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing